117 related articles for article (PubMed ID: 16475213)
1. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.
Milella M; Gelibter AJ; Pino MS; Bossone G; Marolla P; Sperduti I; Cognetti F
Oncologist; 2010; 15(2):e1-4. PubMed ID: 20189980
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Inoue H; Todaka A; Yamazaki K; Fushiki K; Shirasu H; Kawakami T; Tsushima T; Hamauchi S; Yokota T; Machida N; Fukutomi A; Onozawa Y; Andoh A; Yasui H
Invest New Drugs; 2021 Oct; 39(5):1399-1404. PubMed ID: 33835357
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.
Valle JW; Wasan H; Johnson P; Jones E; Dixon L; Swindell R; Baka S; Maraveyas A; Corrie P; Falk S; Gollins S; Lofts F; Evans L; Meyer T; Anthoney A; Iveson T; Highley M; Osborne R; Bridgewater J
Br J Cancer; 2009 Aug; 101(4):621-7. PubMed ID: 19672264
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
Fiteni F; Nguyen T; Vernerey D; Paillard MJ; Kim S; Demarchi M; Fein F; Borg C; Bonnetain F; Pivot X
Cancer Med; 2014 Dec; 3(6):1502-11. PubMed ID: 25111859
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers.
Gedela S; Munot P; Vaidyanathan A; Joarder R; Chaugule D; Parulekar M; Nashikkar C; Ghadi A; Vadodaria D; Goel M; Patkar S; Mandavkar S; Ramaswamy A; Bhargava P; Srinivas S; Ostwal V
J Gastrointest Cancer; 2024 Mar; 55(1):263-269. PubMed ID: 37368175
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for biliary tract cancer: real-world experience in a single institute.
Maeda O; Ebata T; Shimokata T; Matsuoka A; Inada-Inoue M; Morita S; Takano Y; Urakawa H; Miyai Y; Sugishita M; Mitsuma A; Ando M; Mizuno T; Nagino M; Ando Y
Nagoya J Med Sci; 2020 Nov; 82(4):725-733. PubMed ID: 33311803
[TBL] [Abstract][Full Text] [Related]
9. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).
McNamara MG; Goyal L; Doherty M; Springfeld C; Cosgrove D; Sjoquist KM; Park JO; Verdaguer H; Braconi C; Ross PJ; Gramont A; Zalcberg JR; Palmer DH; Valle JW; Knox JJ
Future Oncol; 2020 Jun; 16(16):1069-1081. PubMed ID: 32374623
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
Toyoda M; Ajiki T; Fujiwara Y; Nagano H; Kobayashi S; Sakai D; Hatano E; Kanai M; Nakamori S; Miyamoto A; Tsuji A; Kaihara S; Ikoma H; Takemura S; Toyokawa H; Terajima H; Morita S; Ioka T
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1295-301. PubMed ID: 24614947
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Ocean AJ; Christos P; Sparano JA; Matulich D; Kaubish A; Siegel A; Sung M; Ward MM; Hamel N; Espinoza-Delgado I; Yen Y; Lane ME
Cancer Chemother Pharmacol; 2011 Aug; 68(2):379-88. PubMed ID: 20981545
[TBL] [Abstract][Full Text] [Related]
12. Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study.
Chiang NJ; Chen MH; Yang SH; Hsu C; Yen CJ; Tsou HH; Su YY; Chen JS; Shan YS; Chen LT
Liver Int; 2020 Oct; 40(10):2535-2543. PubMed ID: 32463975
[TBL] [Abstract][Full Text] [Related]
13. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Kehmann L; Berres ML; Gonzalez-Carmona M; Modest DP; Mohr R; Wree A; Venerito M; Strassburg C; Keitel V; Trautwein C; Luedde T; Roderburg C
BMC Cancer; 2023 May; 23(1):470. PubMed ID: 37217885
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Mizusawa J; Morizane C; Okusaka T; Katayama H; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2016 Apr; 46(4):385-8. PubMed ID: 27025903
[TBL] [Abstract][Full Text] [Related]
15. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
Target Oncol; 2024 May; ():. PubMed ID: 38691295
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.
Olkus A; Tomczak A; Berger AK; Rauber C; Puchas P; Wehling C; Longerich T; Mehrabi A; Chang DH; Liermann J; Schäfer S; Pfeiffenberger J; Jäger D; Michl P; Springfeld C; Dill MT
Target Oncol; 2024 Mar; 19(2):213-221. PubMed ID: 38416377
[TBL] [Abstract][Full Text] [Related]
17. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment.
Wang Z; Xu L; Wang H; Li Z; Lu L; Li X; Zhang Q
Saudi J Biol Sci; 2018 Jul; 25(5):909-916. PubMed ID: 30108440
[TBL] [Abstract][Full Text] [Related]
18. Case report: From palliative to potentially curative - the advent of immunotherapy providing hope to advanced gallbladder adenocarcinoma.
Leong EKF; Tan NCH; Pang NQ; Kow AWC
Front Immunol; 2024; 15():1353430. PubMed ID: 38370411
[TBL] [Abstract][Full Text] [Related]
19. Current therapy and future directions in biliary tract malignancies.
Ciombor KK; Goff LW
Curr Treat Options Oncol; 2013 Sep; 14(3):337-49. PubMed ID: 23686724
[TBL] [Abstract][Full Text] [Related]
20. Combination anlotinib and toripalimab for an advanced biliary tract cancer patient with high Eastern Cooperative Oncology Group performance status: a case report.
Liu L; Chen B; Tang M; Guo Y; Hou J; Zhou W; Zhu X
Anticancer Drugs; 2024 May; ():. PubMed ID: 38728054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
